Theriva Biologics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 09/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $8.6M | $12.0M | $14.3M | $11.7M | — |
| Operating expenses | $24.1M | $26.3M | $21.4M | $21.6M | — |
| Operating income | -$24.1M | -$26.3M | -$21.4M | -$21.6M | — |
| Pretax income | -$23.7M | -$25.7M | -$20.0M | -$21.1M | — |
| Income tax expense | — | $0 | -$1.6M | -$1.4M | — |
| Net income | -$23.7M | -$25.7M | -$18.3M | -$19.7M | — |
| Balance Sheet | |||||
| Cash and equivalents | $13.1M | $11.6M | $23.2M | $41.8M | $50.5M |
| Current assets | $17.5M | $16.3M | $27.4M | $45.5M | $52.7M |
| Total assets | $38.2M | $35.4M | $55.2M | $71.9M | $77.1M |
| Current liabilities | $10.0M | $7.6M | $6.7M | $7.1M | $12.3M |
| Total liabilities | $22.9M | $16.3M | $15.5M | $17.3M | $18.0M |
| Stockholders' equity | $15.4M | $19.1M | $37.0M | $51.8M | $56.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$16.7M | -$16.9M | -$19.0M | -$19.1M | — |
| Depreciation and amortization | $108,000 | $137,000 | $135,000 | $85,000 | — |
| Stock-based compensation | $654,000 | $671,000 | $552,000 | $475,000 | — |
| Capital expenditure | $35,000 | $1,000 | $202,000 | $116,000 | — |
| Free cash flow | -$16.7M | -$16.9M | -$19.2M | -$19.2M | — |
| Share repurchases | — | — | $0 | $288,000 | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 45.9M · Free float 91.1%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.